WoS İndeksli Yayınlar Koleksiyonu

Permanent URI for this collectionhttps://hdl.handle.net/20.500.14627/6

Browse

Filters

2025 - 20264

Settings

Publication Index: search.filters.publicationIndex.PubMedSubject: search.filters.subject.Breast Cancer

Search Results

Now showing 1 - 4 of 4
  • Article
    Novel Hydrazide-Hydrazone Derivatives Containing Flurbiprofen 1,2,4-Triazole as Anticancer Agents: Design, Synthesis and Biological Evaluation
    (Slovensko Kemijsko Drustvo, 2026) Küçükgüzel, Ş. Güziz; Gökoğlan, Ecem; Yılmaz, Özgür; Çevik, Özge; Çakıcı, Çiğdem; Erdoğan, Ömer
    Hydrazone derivatives are one of the scaffolds frequently used in new drug development studies. Due to the promising pharmacological effects of the hydrazone structure, fifteen new hydrazide-hydrazone compounds containing flurbiprofen 1,2,4-triazole were synthesized in this study and their in vitro anticancer effects were tested. All compounds were tested for cytotoxic effects against breast cancer cell lines (MCF-7 and MDA-MB231), and glioblastoma cell line (U87) by using MTT assay. Among the synthesized compounds, compounds 7a and 7c exhibited the most potent cytotoxic activity with IC50 values of 7.80 +/- 1.20 & micro;M and 2.40 +/- 0.93 & micro;M against MCF-7 cell line, while compound 7a showed the highest activity with IC50 value of 7.63 +/- 1.05 & micro;M against MDA-MB231 cell line. In addition, compounds 7c and 7n presented cytotoxic activity with IC50 values of 10.31 +/- 4.63 & micro;M and 10.81 +/- 6.11 & micro;M against U87 cell line. The possible cytotoxic effects of compounds on mouse fibroblast cell line (L929) were assessed for their safety and compounds 7a, 7c, and 7n were found less toxic than 5-fluorourasil. Additionally, compound 7c was further studied to investigate its effects on apoptosis and PI3K activity, which play a role in cancer development. The results showed that compound 7c increased apoptosis in MCF-7 cells and it displayed PI3K enzyme inhibitory activity. Our study revealed that the synthesized hydrazone compounds have the potential to be lead compounds for further studies on cancer.
  • Article
    Exploring E-Health Literacy Levels among Turkish Women Diagnosed with Breast Cancer: A Cross-Sectional Study
    (BMC, 2026) Akkurt, Burcu; Coskunsu, Dilber Karagozoglu; Reyhanioglu, Duygu Aktar; Simsek, Mine; Tosun, Anil; Yilmaz, Nergis; Koseoglu, Aygul
    Access to digital health information has increased for women diagnosed with breast cancer; however, searching, understanding, and interpreting this information requires adequate e-health literacy. This study aimed to determine the e-health literacy levels of women diagnosed with breast cancer and to examine the relationship between e-health literacy and selected sociodemographic and clinical characteristics. In addition, women's awareness of e-health and telerehabilitation concepts, as well as their internet use patterns, were evaluated to inform future digital health initiatives. Data were collected through face-to-face and online methods using an Information Form to assess participant characteristics and the E-health Literacy Scale to measure e-health literacy. The study included 336 voluntary Turkish-speaking women aged 18 years and older diagnosed with breast cancer.The median e-health literacy score on the E-health Literacy Scale was 25 (range: 8-40), with a mean score of 24.6 +/- 7.62. E-health literacy levels were significantly associated with age, educational level, time since diagnosis, and awareness of e-health and telerehabilitation concepts (p < .05), with lower scores observed among older women. In multivariable linear regression analysis, these sociodemographic and care-related factors jointly explained approximately 47% of the variance in e-health literacy levels. Overall, the findings indicate that women with breast cancer in Türkiye have limited awareness of e-health and telerehabilitation concepts, and that e-health literacy levels are significantly associated with age, educational level, time since diagnosis, and awareness of telerehabilitation. These results underscore the importance of developing targeted digital health education initiatives and awareness-based interventions to enhance e-health literacy and support equitable access to digital health services among breast cancer survivors.
  • Article
    Investigation of Novel Nimesulide Derivatives Against Breast Cancer
    (Academic Press Inc Elsevier Science, 2025) Birgul, Kaan; Atlihan, Irem; Dere, Damla; Yelekci, Kemal; Tiber, Pinar Mega; Orun, Oya; Kucukguzel, S. Guniz
    This study focused on the synthesis of novel nimesulide semicarbazone derivatives and the evaluation of their cytotoxic potential against luminal-A (MCF-7) and triple-negative (MDA-MB-231) breast cancer cell lines. Additionally, their effects on mitochondrial membrane potential (MMP), apoptosis, and mitogen-activated protein kinase (MAPK) pathway modulation were investigated. Breast cancer remains the most prevalent malignancy among women, with luminal-A and triple-negative subtypes posing significant therapeutic challenges due to drug resistance and the lack of effective targeted treatments. The MAPK pathway plays a crucial role in breast cancer progression, making its inhibition a promising therapeutic approach. Non-steroidal anti-inflammatory drugs (NSAIDs), particularly nimesulide, have demonstrated anticancer potential beyond their well-established anti-inflammatory properties. Accordingly, the semicarbazone moiety was incorporated into the molecular scaffold to enhance the antiproliferative efficacy of nimesulide derivatives, as it has been reported to exhibit cytotoxic and apoptosis-inducing effects across various cancer cell lines. A series of nimesulide semicarbazone derivatives (5a-m) were synthesized through multi-step reactions and characterized using elemental analysis, FT-IR, 1H NMR, 13C NMR and Mass spectroscopy (5e). In silico studies were performed to predict their binding affinities to MAPK12. The cytotoxic effects of the synthesized compounds were assessed by determining IC50 values in MCF-7 and MDA-MB-231 cell lines (CCK8 test). Compounds exhibiting strong cytotoxic activity were further examined for their impact on MMP depolarization (JC-1 assay), apoptosis induction (Annexin V-FITC/PI staining), and MAPK pathway modulation (Western blotting of p-ERK and ERK protein). Molecular docking results indicated that the synthesized compounds exhibited favorable interactions with MAPK12, with compound 5e showing one of the highest binding affinity (-9.29 kcal/mol, Ki = 0.154 mu M). Cytotoxicity assays revealed that compound 5e had the lowest IC50 values (11.77 +/- 0.26 mu M in MCF-7; 20.72 +/- 0.25 mu M in MDA-MB-231), demonstrating significantly higher cytotoxicity than nimesulide. JC-1 assays confirmed that compound 5e induced MMP depolarization at higher concentrations, suggesting apoptosis activation. Flow cytometry analysis further validated a substantial increase in apoptotic cell populations following treatment with compound 5e. Western blot results showed a dose-dependent decrease in p-ERK levels in both MCF-7 and MDA-MB-231 cells, confirming MAPK pathway inhibition. These findings support that nimesulide-based semicarbazones, particularly compound 5e, exhibit potent antiproliferative and pro-apoptotic activity via MAPK pathway modulation, offering a promising avenue for the development of targeted breast cancer therapies.
  • Article
    Citation - WoS: 2
    Citation - Scopus: 3
    Biological Activities of Etodolac-Based Hydrazone, Thiazolidinone and Triazole Derivatives on Breast Cancer Cell Lines MCF-7 and MDA-MB
    (Wiley, 2025) Sevinc, Sevgi Kocyigit; Cikla-Suzgun, Pelin; Tiber, Pinar Mega; Kucukguzel, S. Guniz; Orun, Oya; Güniz Küçükgüzel, Ş.
    In this study, several etodolac-based hydrazone, thiazolidinone, and triazole derivatives that we synthesized and characterized in our earlier research were tested against the hormone-responsive breast cell line MCF-7 and the triple-negative MDA-MB-231, as well as the murine origin fibroblast cell line L-929, at varying doses for their effects on cell viability and toxicity and for their inhibitory activity on cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) formation. Cell viability and apoptosis tests were utilized to assess the anti-cancer potential of etodolac and its derivatives after the cells were exposed to varied concentrations of synthesized compounds for three different time periods. ELISA and Western blot methods were used to detect protein levels. All synthesized compounds demonstrated higher anti-cancer activity at significantly lower doses compared to etodolac (half-maximal inhibitory concentration [IC50] of 0-50 mu M range in derivatives versus 0.5-1 mM range in etodolac). Except for SGK 242, which had a major toxic effect on all cells, the chemicals SGK 206 and SGK 217 had a twice-less impact on control murine L-929 fibroblasts. Similar to proliferation, low concentrations of SGK 206 and SGK 217 (25-50 mu M) significantly induced apoptosis in breast cancer cells but not in normal cells. Additionally, they inhibited COX-2 protein expression at 50 mu M, and SGK 206 inhibited PGE2 release more effectively than etodolac in cancer cells. The results of this study suggest that, in comparison to a healthy control group, the thiazolidinone derivative SGK 206 and the thiazolidinone derivative SGK 217 are more effective than etodolac when it comes to the breast cancer cell lines MCF-7 and MDA-MB-231. SGK 206 exhibits a low IC50 value, a distinct dose-response relationship, and strong apoptotic effects, particularly on MDA-MB-231 cells.